

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>				<b>Complete if Known</b>	
				Application Number	10/785,374
				Filing Date	2/24/2004
				First Named Inventor	Summar et al.
				Art Unit	1638
				Examiner Name	Diana B. Johannsen
				Attorney Docket Number	1242/58 CIP
Sheet	1	of	7		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B.J.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/785,374
			Filing Date	2/24/2004
			First Named Inventor	Summar et al.
			Art Unit	1638
			Examiner Name	Diana B. Johannsen
(Use as many sheets as necessary)			Attorney Docket Number	1242/58 CIP
Sheet	2	of	7	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	2	Abman et al., "Role of endothelium-derived relaxing factor during transition of the pulmonary circulation at birth," Am. J. Physiol., Vol. 259, pgs. H1921-H1927 (1990).	
	3	Abman, S. H.; Arch Dis Child Fetal Neonatal Ed (2002) 87: F15-F18.	
	4	Adelman et al., "In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone," DNA, Vol. 2, pg. 183-193 (1983).	
	5	Advisory Action corresponding to U.S. Patent Application Serial No. 12/364,078 dated March 9, 2011.	
	6	Allen, J. and ATS subcommittee AoP, Am J Respir Crit Care Med (2003) 168: 356-396.	
	7	Artymiuk et al., "Biotin carboxylase comes into the fold," Nature Struct. Biol., Vol. 3, pgs. 128-132 (1996).	
	8	Bachmann et al., New England Journal of Medicine, Vol. 304, pg. 543 (1981).	
	9	Batshaw and Brusilow, "Valproate-induced hyperammonemia," Annals of Neurology, Vol. 11, No. 3, pgs. 319-21 (1982).	
	10	Bearman, S.I., "Venocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation," Journal of Clinical Oncology, Vol. 11, pgs. 1729-1736 (1993).	
	11	Beaucage et al., "Deoxynucleoside phosphoramidites - a new class of key intermediates for deoxypolynucleotide synthesis," Tetrahedron Letters, Vol. 22, pgs. 1859-1862 (1981).	
	12	Beaumier, L., "Arginine: New and exciting developments for an 'old' amino acid," Biomedical & Environmental Sciences, Vol. 9, pgs. 296-315 (1996).	
	13	Becker et al., Archives of Biochemistry & Biophysics, Vol. 223, pgs. 381-392 (1983).	
	14	Bernard et al., Intensive Care Medicine, Vol. 20, pgs. 225-32 (1994).	
	15	Boger, R. H., Curr Opin Clin Nutr and Met Care (2008) 11:55-61.	
	16	Bourrier et al., Prese Medicale, Vol. 17, pgs. 2063-2066 (1988).	
	17	Caroline et al., "Acute L-arginine supplement and cardiac surgery," Canadian J. Anesth., /D.B.J./ Vol. 43, pg. A16 (1996). Dagensis, C. et al (correct author name)	
	18	Castillo et al., "Whole body arginine metabolism and nitric oxide synthesis in newborns with persistent pulmonary hypertension," Pediatr. Res., Vol. 38, pgs. 17-24 (1995).	
	19	<del>Castillo et al., Journal of Biological Chemistry, Vol. 264, pgs. 4038-44 (1989).</del>	
	20	Castro-Gago et al., Child Neuro Systems, Vol. 6, pgs. 434-436 (1990).	
	21	Cervera et al., "Photoaffinity labeling with UMP of lysine 992 of carbamyl phosphate synthetase from Escherichia coli allows identification of the binding site for the pyrimidine inhibitor," Biochemistry, Vol. 35, pgs. 7247-7255 (1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B.J.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/785,374
			Filing Date	2/24/2004
			First Named Inventor	Summar et al.
			Art Unit	1638
			Examiner Name	Diana B. Johannsen
(Use as many sheets as necessary)			Attorney Docket Number	1242/58 CIP
Sheet	3	of	7	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	22	Cheung et al., "Channeling of Urea Cycle Intermediates in Situ in Permeabilized Hepatocytes," J. Biol. Chem., Vol. 264, pgs. 4038-4044 (1989).	
	23	Cohen P. P., Current Topics in Cellular Regulation, Vol. 18, pgs. 1-19 (1981).	
	24	Conner et al., Proc. Natl. Acad. Sci. U.S.A. 80:278(1983).	
	25	Coude et al., J. Clin. Invest., Vol. 64, pgs. 1544-1551 (1979).	
	26	Coulter et al., Lancet, Vol. 1, No. 8181, pgs. 1310-1311 (1980).	
	27	Crea et al., Proc. Natl. Acad. Sci. USA, Vol. 75, pgs. 5765-5769 (1978).	
	28	de Groot et al., Biochemical & Biophysical Research Communications, Vol. 124, pgs. 882-888 (1984).	
	29	Eadie et al., "Valproate-associated hepatotoxicity and its biochemical mechanisms," Med. Toxicol., Vol. 3, pgs. 85-106 (1998).	
	30	Eichenlaub et al., "Mutants of the mini-F plasmid pML31 thermosensitive in replication," J. Bacteriol., Vol. 138, pgs. 559-566 (1979).	
	31	Faber-Langendoen et al., <i>Bone Marrow Transplantation</i> , Vol. 12, pgs. 501-507 (1993).	
	32	Fike, C. D. et al., J Appl Physiol (2000) 88:1797-1803.	
	33	Fike, C. D., et al., American Journal of Physiology (Lung, Cellular and Molecular Physiology 18) (1998) 274:L517-L526	
	34	Gribskov et al., "Sigma factors from E. coli, B. subtilis, phage SP01, and phage T4 are homologous proteins," Nucl. Acids. Res., Vol. 14, pgs. 6745-6763 (1986).	
	35	Hauser et al., "Allopurinol-induced orotidinuria," New England Journal of Medicine, Vol. 322, pgs. 1641-1645 (1990).	
	36	Hebert, P.C., "A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome," Chest, Vol. 104, pgs. 230-235 (1993).	
	37	Jackson M. J., Annual Review of Genetics, Vol. 20, pgs. 431-64 (1986).	
	38	Javid-Majd et al., "Comparison of the Functional Differences for the Homologous Residues within the Carboxy Phosphate and Carbamate Domains of Carbamoyl Phosphate Synthetase," Biochemistry, Vol. 35, pgs. 14362-14369 (1996).	
	39	Jones et al., "Venocclusive disease of the liver following bone marrow transplantation," Transplantation, Vol. 44, pgs. 778-783 (1987).	
	40	Kamoun et al., "Valproate-induced inhibition of urea synthesis," Lancet, Vol. 1, pg. 48 (1987).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B.J.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/785,374
			Filing Date	2/24/2004
			First Named Inventor	Summar et al.
			Art Unit	1638
			Examiner Name	Diana B. Johannsen
			Attorney Docket Number	1242/58 CIP
Sheet	4	of	7	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	41	Kinsella et al., "Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn," Lancet, Vol. 340, pgs. 819-820 (1992)	
	42	Kyte & Doolittle, "A simple method for displaying the hydropathic character of a protein," J. Mol. Biol., Vol. 157, pgs. 105-132 (1982).	
	43	Landgren et al., Science, 241:1007, (1988).	
	44	Landgren et al., Science, 242:229-237, (1988).	
	45	Lipsitz et al., "Endogenous nitric oxide and pulmonary vascular tone in the neonate," J. Pediatr. Surg., Vol. 31, pgs. 137-140 (1996)	
	46	Liu and Sommer, "Restriction endonuclease fingerprinting (REF): a sensitive method for screening mutations in long, contiguous segments of DNA," Biotechniques, Vol. 18, No. 3, pgs. 470-477 (1995).	
	47	Liu, et al., Am J Physiol Lung Cell Mol Physiol (2006) 290:L2-L10.	
	48	Maniatis et. al., in <i>Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor, N.Y., pgs. 280-281 (1982).	
	49	Marrini et al., "Hepatic and renal contributions to valproic acid-induced hyperammonemia," Neurology, Vol. 38, pgs. 365-371(1988).	
	50	Marshall et al., "Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome," Critical Care Medicine, Vol. 23, pgs. 1638-1652 (1995).	
	51	Matuschak and Rinaldo, "Organ interactions in the adult respiratory distress syndrome during sepsis. Role of the liver in host defense," Chest, Vol. 94, pgs. 400-406 (1988).	
	52	Matuschak et al., American Review of Respiratory Disease, Vol. 141, pgs. 1296-1306 (1990).	
	53	Matuschak, G. M., "Lung-liver interactions in sepsis and multiple organ failure syndrome," Clinics in Chest Medicine, Vol. 17, pgs. 83-98 (1996).	
	54	McCaffrey et al., "Effect of L-Arginine Infusion on Infants with Persistent Pulmonary Hypertension of the Newborn," Biol. Neonate, Vol. 67, No. 4, pgs. 240-243 (1995).	
	55	McDonald et al., "Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients," Annals of Internal Medicine, Vol. 118, pgs. 255-267 (1993).	
	56	Meier, U., Pharm Stat (2006) 5:253-263.	
	57	Meister, A., "Mechanism and regulation of the glutamine-dependent carbamyl phosphate synthetase of Escherichia coli," Adv. Enzymol. Relat. Areas Mol. Biol., Vol. 62, pgs. 315-374 (1989).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 7

**Complete if Known**

Application Number	10/785,374
Filing Date	2/24/2004
First Named Inventor	Summar et al.
Art Unit	1638
Examiner Name	Diana B. Johannsen
Attorney Docket Number	1242/58 CIP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	58	Messing et al., <i>Third Cleveland Symposium on Macro Molecular and Recombinant DNA</i> , Ed. Walton, A., (Elsevier, Amsterdam) (1981).	
	59	Mitchell et al., "Syndrome of Idiopathic Hyperammonemia after High-Dose Chemotherapy: Review of Nine Cases," <i>American Journal of Medicine</i> , Vol. 85, No. 5, pgs. 662-667 (1988).	
	60	Moncada et al., "The L-Arginine-Nitric Oxide Pathway," <i>New England Journal of Medicine</i> , Vol. 329, pgs. 2002-2012 (1993).	
	61	Moorman et al., "Expression patterns of mRNAs for ammonia-metabolizing enzymes in the developing rat: the ontogenesis of hepatocyte heterogeneity," <i>Histochemical Journal</i> , Vol. 22, pgs. 457-468 (1990).	
	62	Mupanemunda, R. H., <i>Early Human Development</i> (1997) 47: 247-262.	
	63	Needleman et al., "A general method applicable to the search for similarities in the amino acid sequence of two proteins," <i>J. Mol. Biol.</i> , Vol. 48, pgs. 443-453 (1970).	
	64	Nuzum, "Urea Cycle Enzyme Adaptation to Dietary Protein in Primates," <i>Science</i> , Vol. 172, pgs. 1042-1043 (1971).	
	65	Office Action corresponding to U.S. Patent Application Serial No. 12/322,434 dated April 5, 2011.	
	66	Office Action corresponding to U.S. Patent Application Serial No. 12/122,117 dated March 23, 2011.	
	67	Office Action corresponding to EP Patent Application Serial No. 10184493 dated March 30, 2011	
	68	Office Action corresponding to EP Patent Application Serial No. 05723789 dated March 31, 2011	
	69	Palmer et al., "L-Arginine is the Physiological Precursor for the Formation of Nitric Oxide in Endothelium-Dependent Relaxation," <i>Biochem. Biophys. Res. Commun.</i> , Vol. 153, pgs. 1251-1256 (1988).	
	70	Pierson, D.L., "A rapid colorimetric assay for carbamyl phosphate synthetase I," <i>J. Biochem. Biophys. Methods</i> , Vol. 3, pgs. 31-37 (1980).	
	71	Price et al., "Prognostic Indicators for Blood and Marrow Transplant Patients Admitted to an Intensive Care Unit," <i>American Journal of Respiratory &amp; Critical Care Medicine</i> , Vol. 158, pgs. 876-884 (1998).	
	72	Rabier et al., "Effects of organic acids on the synthesis of citrulline by intact rat liver mitochondria," <i>Biochimie</i> , Vol. 68, pgs. 639-647 (1986).	
	73	Rabier et al., "Propionate and succinate effects on acetyl glutamate biosynthesis by rat liver mitochondria," <i>Biochem. &amp; Biophys. Research Comm.</i> , Vol. 91, pgs. 456-460 (1979).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B.J.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/785,374	
			Filing Date	2/24/2004	
			First Named Inventor	Summar et al.	
			Art Unit	1638	
			Examiner Name	Diana B. Johannsen	
Sheet	6	of	7	Attorney Docket Number	1242/58 CIP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	74	Raiha and Suihkonen, J. Acta Paediatrica Scand., Vol. 57, pgs. 121-127 (1968).	
	75	Richardson et al., "Prevention and treatment of hepatic venoocclusive disease after high-dose cytoreductive therapy," Leukemia & Lymphoma, Vol. 31, pgs. 267-277 (1998).	
	76	Rinaldo et al., "Nitric oxide inactivates xanthine dehydrogenase and xanthine oxidase in interferon-gamma-stimulated macrophages," American Journal of Respiratory Cell & Molecular Biology, Vol. 11, pgs. 625-630 (1994).	
	77	Roberts, J. D., et al., "Inhaled nitric oxide in persistent pulmonary hypertension of the newborn," Lancet, Vol. 340, pgs. 818-819 (1992)	
	78	Rodriguez-Aparicio, L. B. et al., Biochemistry, Vol. 28, pgs. 3070-3074 (1989).	
	79	Rubio, V., (Review) Biochemical Society Transactions, Vol. 21, pgs. 198-202 (1993).	
	80	Saiki et al., "A Novel Method for the Detection of Polymorphic Restriction Sites by Cleavage of Oligonucleotide Probes: Application to Sick Cell Anemia," Bio/Technology, Vol. 3, pgs. 1008-1012 (1985).	
	81	Schmid, R. D., Clin. Chim. Acta., Vol. 74, pgs. 39-42 (1977).	
	82	Schwartz et al. eds. <i>Atlas of Protein Sequence and Structure</i> . National Biomedical Research Foundation, pp. 357-358 (1979).	
	83	Shigesada et al., Journal of Biological Chemistry, Vol. 246, pgs. 5588-5595 (1971).	
	84	Shimoda L., et al., Physiol Res (2000) 49:549-560.	
	85	Shulman et al., "Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms," Hepatology, Vol. 19, pgs. 1171-81 (1994).	
	86	Smith et al., "Comparisons of biosequences," Adv. Appl. Math., Vol. 2, pgs. 482-489 (1981).	
	87	Stapleton et al., "Comparison of the Functional Differences for the Homologous Residues Within the Carboxy Phosphate and Carbamate Domains of Carbamoyl Phosphate Synthetase," Biochemistry, Vol. 35, pgs. 14352-14361 (1996).	
	88	Subhedar, N. V., Acta Paediatr suppl (2004) 444:29-32.	
	89	Summar ML, et al., "Physical and linkage mapping of human carbamyl phosphate synthetase I (CPS1) and reassignment from 2p to 2q35," Cytogenetics & Cell Genetics, Vol. 71, pgs. 266-267 (1995).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/785,374
				Filing Date	2/24/2004
				First Named Inventor	Summar et al.
				Art Unit	1638
				Examiner Name	Diana B. Johannsen
				Attorney Docket Number	1242/58 CIP
Sheet	7	of	7		

[illegible]

Examiner Signature	/Diana B. Johannsen/	Date Considered	/D.B.J./
--------------------	----------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B.J.